Biochemical and Biophysical Research Communications, Vol.508, No.2, 380-386, 2019
Lactosylceramide synthase beta-1,4-GalT-V: A novel target for the diagnosis and therapy of human colorectal cancer
Little is known about an oncogenic signal transducer beta-1,4-galactosyltransferase-V (beta-1,4-GalT-V), in human colorectal cancer. Using quantitative RT-PCR, immunohistochemical staining and ELISA assays, we determined that beta-1,4-GalT-V gene/protein expression is specifically increased in human colorectal cancer (CRC) tumors, compared to visibly normal tissue. Furthermore, we observed a marked increase in its enzymatic activity, and its product lactosylceramide. Moreover, we found increased dihydrosphingolipid metabolites, in particular dihydrosphingomyelin in cancer tissue compared to normal. Further, inhibition of glycosphingolipid synthesis by the synthetic ceramide analog, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (D-PDMP), concurrently inhibited colorectal cancer cell (HCT-116) proliferation, as well as beta-1,4-GalT-V mass and several glycosphingolipid levels. We conclude that beta-1,4-GalT-V may serve as a diagnostic and therapeutic biomarker for the progression of human colorectal cancer, and consequently, inhibition of GSL synthesis may be a novel approach for the treatment of this life-threatening disease. (C) 2018 Published by Elsevier Inc.